Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PrEP
Pharma
Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales
The company raised its previous guidance of $800 million in revenues from the long-acting injectable.
Zoey Becker
May 8, 2026 11:30am
Manufacturing is key to Gilead's Yeztugo PrEP rollout: exec
Mar 13, 2026 10:33am
'One2PrEP': Gilead's 1st Yeztugo ad highlights biannual dosing
Mar 2, 2026 3:39pm
Gilead lifts guidance on PrEP launch despite cell therapy woes
Oct 31, 2025 11:51am
GSK touts study showing tolerability edge for its long-acting PrEP
Oct 15, 2025 8:45am
Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia
Sep 26, 2025 10:00am
